Citigroup Inc Cytom X Therapeutics, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.41 - $2.74 $174,350 - $338,809	123,653 New	123,653 $269,000
Q3 2022 Nov 10, 2022	SELL	$1.23 - $1.97 $1,084 - $1,737	-882 Reduced 52.59%	795 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.53 - $2.89 $4,051 - $7,652	-2,648 Reduced 61.23%	1,677 $3,000
Q1 2022 May 12, 2022	SELL	$2.67 - $4.68 $337,605 - $591,757	-126,444 Reduced 96.69%	4,325 $11,000
Q4 2021 Feb 10, 2022	BUY	$3.87 - $7.39 $82,431 - $157,407	21,300 Added 19.46%	130,769 $566,000
Q3 2021 Nov 10, 2021	BUY	$4.32 - $6.43 $472,906 - $703,885	109,469 New	109,469 $557,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.